What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
John Nemunaitis mainly focuses on Internal medicine, Immunology, Surgery, Oncology and Clinical trial.
John Nemunaitis combines topics linked to Gastroenterology with his work on Internal medicine.
John Nemunaitis has researched Immunology in several fields, including Cancer research, Adverse effect and non-small cell lung cancer.
His study in the field of Chills is also linked to topics like Lactate dehydrogenase.
His research in the fields of Belagenpumatucel-L overlaps with other disciplines such as In patient.
His Clinical trial study incorporates themes from Cancer and Randomized controlled trial.
His most cited work include:
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (1677 citations)
- Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (1155 citations)
- A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer (986 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Cancer research, Immunology and Cancer.
The Internal medicine study combines topics in areas such as Gastroenterology and Surgery.
John Nemunaitis has included themes like Clinical trial, Bone marrow and Urology in his Surgery study.
His work carried out in the field of Oncology brings together such families of science as Pathology, Adverse effect and Immunotherapy.
His Cancer research research is multidisciplinary, incorporating elements of Carcinogenesis, Gene, Genetic enhancement and Viral vector.
His work focuses on many connections between Cancer and other disciplines, such as Bioinformatics, that overlap with his field of interest in Computational biology and RNA interference.
He most often published in these fields:
- Internal medicine (47.03%)
- Oncology (30.30%)
- Cancer research (25.64%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (47.03%)
- Oncology (30.30%)
- Cancer research (25.64%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Cancer research, Immunotherapy and In patient.
His research investigates the connection with Internal medicine and areas like Gastroenterology which intersect with concerns in Refractory.
His work deals with themes such as Biomarker, Toxicity, Chemotherapy and Immune checkpoint inhibitors, which intersect with Oncology.
His study on Cancer research also encompasses disciplines like
- Immune system that intertwine with fields like Cell,
- Plasmid and related Transfection.
John Nemunaitis interconnects Radiation therapy, Sarcoma and Lymphoma in the investigation of issues within Immunotherapy.
His Cancer study combines topics from a wide range of disciplines, such as Regimen and Precision medicine.
Between 2016 and 2021, his most popular works were:
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. (101 citations)
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial (70 citations)
- Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC). (61 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Pharmacokinetics, Pharmacology, Oncology and Tolerability.
Internal medicine is frequently linked to Gastroenterology in his study.
His work in the fields of Pharmacokinetics, such as Pharmacodynamics, intersects with other areas such as Ketoconazole and Ixazomib.
His studies deal with areas such as Clarithromycin and Concomitant as well as Pharmacology.
His Oncology research is multidisciplinary, relying on both Immunohistochemistry, Clinical trial, Antibody-drug conjugate and Immunotherapy.
His study looks at the relationship between Chemotherapy and topics such as Pathology, which overlap with Immune system.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
